{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:05:35Z","timestamp":1792508735500,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy, classified as congenital TTP (cTTP) and immune TTP (iTTP). iTTP represents the most common clinical subtype, accounting for approximately 95% of cases. Primary clinical features include microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neuropsychiatric symptoms, fever, and renal involvement. Reduced ADAMTS13 activity and dysregulation of the complement pathway contribute to the pathogenesis of iTTP. First-line therapy for newly diagnosed iTTP, comprising plasma exchange and corticosteroids, demonstrates reasonable efficacy. However, some patients experience disease relapse with suboptimal response to plasma exchange. These relapsed and refractory cases pose significant therapeutic challenges and are associated with an extremely poor prognosis and high mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Here, we report a case of relapsed and refractory iTTP presenting with scleral icterus, thrombocytopenia, altered mental status, fever, and renal impairment. Despite initial treatment with plasma exchange, corticosteroids, ripertamab, and intravenous immunoglobulin, the patient\u2019s condition deteriorated rapidly. Laboratory tests revealed elevated levels of the terminal complement complex (C5b-9) and complement factor Ba in the patient. Consequently, we initiated treatment with the complement inhibitor iptacopan, combined with plasma exchange, corticosteroids, and rituximab. The hemoglobin and platelet count increased significantly by Day 5. At the 5-week follow-up, ADAMTS13 activity, hemoglobin, and platelet counts had all normalised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case is a preliminary observation. With biomarker evidence supporting alternative pathway activation (e.g., elevated Ba and sC5b-9), it reports for the first time the potential association of combined therapy involving plasma exchange, corticosteroids, rituximab, and iptacopan with rapid clinical improvement in a patient with relapsed and refractory iTTP. It provides initial experience for exploring complement alternative pathway inhibition as a potential adjunctive strategy for such patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-026-00854-9","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:16:49Z","timestamp":1774437409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The complement factor B inhibitor iptacopan for relapsed and refractory immune thrombotic thrombocytopenic purpura"],"prefix":"10.1186","volume":"24","author":[{"given":"Minran","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"2","key":"854_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/art.42681","volume":"76","author":"J Leisring","year":"2024","unstructured":"Leisring J, Brodsky SV, Parikh SV. Clinical Evaluation and Management of Thrombotic Microangiopathy. Arthritis Rheumatol. 2024;76(2):153\u201365.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"854_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3324\/haematol.2016.151407","volume":"103","author":"J Hrdinov\u00e1","year":"2018","unstructured":"Hrdinov\u00e1 J, D\u2019Angelo S, Gra\u00e7a NAG, Ercig B, Vanhoorelbeke K, Veyradier A, et al. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica. 2018;103(7):1099\u2013109.","journal-title":"Haematologica"},{"issue":"1","key":"854_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","volume":"2018","author":"T Chiasakul","year":"2018","unstructured":"Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Program. 2018;2018(1):530\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"21","key":"854_CR4","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836\u201346.","journal-title":"Blood"},{"issue":"3","key":"854_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022017023","volume":"141","author":"AJ Doyle","year":"2023","unstructured":"Doyle AJ, Stubbs MJ, Dutt T, Lester W, Thomas W, van Veen J, et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood. 2023;141(3):285\u201394.","journal-title":"Blood"},{"issue":"14","key":"854_CR6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855\u201361.","journal-title":"Blood"},{"issue":"2","key":"854_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312\u201322.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"854_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjh.12707","volume":"164","author":"JP Westwood","year":"2014","unstructured":"Westwood JP, Langley K, Heelas E, Machin SJ, Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol. 2014;164(6):858\u201366.","journal-title":"Br J Haematol"},{"issue":"18","key":"854_CR9","first-page":"2278","volume":"141","author":"M Cugno","year":"2023","unstructured":"Cugno M, Mancini I, Consonni D, De Zan V, Ardissino G, Griffini S, et al. Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2023;141(18):2278\u201382.","journal-title":"Blood"},{"issue":"1","key":"854_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3324\/haematol.2018.198275","volume":"104","author":"EM Staley","year":"2019","unstructured":"Staley EM, Cao W, Pham HP, Kim CH, Kocher NK, Zheng L, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica. 2019;104(1):166\u201375.","journal-title":"Haematologica"},{"issue":"11","key":"854_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, R\u00f6th A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994\u20131008.","journal-title":"N Engl J Med"},{"issue":"3","key":"854_CR12","doi-asserted-by":"publisher","first-page":"e59372","DOI":"10.1371\/journal.pone.0059372","volume":"8","author":"NA Turner","year":"2013","unstructured":"Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS ONE. 2013;8(3):e59372.","journal-title":"PLoS ONE"},{"issue":"Suppl 4","key":"854_CR13","first-page":"S5","volume":"98","author":"A Duval","year":"2023","unstructured":"Duval A, Fr\u00e9meaux-Bacchi V. Complement biology for hematologists. Am J Hematol. 2023;98(Suppl 4):S5\u201319.","journal-title":"Am J Hematol"},{"issue":"11","key":"854_CR14","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1021\/acs.jmedchem.9b01870","volume":"63","author":"N Mainolfi","year":"2020","unstructured":"Mainolfi N, Ehara T, Karki RG, Anderson K, Mac Sweeney A, Liao SM, et al. Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020;63(11):5697\u2013722.","journal-title":"J Med Chem"},{"issue":"16","key":"854_CR15","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"854_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","volume":"78","author":"S Duggan","year":"2018","unstructured":"Duggan S. Caplacizumab: First Global Approval. Drugs. 2018;78(15):1639\u201342.","journal-title":"Drugs"},{"issue":"7","key":"854_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood.2020006052","volume":"137","author":"G Goshua","year":"2021","unstructured":"Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood. 2021;137(7):969\u201376.","journal-title":"Blood"},{"issue":"10","key":"854_CR18","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","volume":"7","author":"M Djulbegovic","year":"2023","unstructured":"Djulbegovic M, Tong J, Xu A, Yang J, Chen Y, Cuker A, et al. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Adv. 2023;7(10):2132\u201342.","journal-title":"Blood Adv"},{"issue":"6","key":"854_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Big\u00e9 N, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733\u201342.","journal-title":"Blood"},{"issue":"11","key":"854_CR20","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","volume":"23","author":"XL Zheng","year":"2025","unstructured":"Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23(11):3711\u201332.","journal-title":"J Thromb Haemost"},{"issue":"24","key":"854_CR21","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","volume":"6","author":"CP Izquierdo","year":"2022","unstructured":"Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, Garc\u00eda-Arroba Peinado J, Cid J, Jimenez MM, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(24):6219\u201327.","journal-title":"Blood Adv"},{"issue":"6","key":"854_CR22","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00277-023-05211-8","volume":"102","author":"T de Oliveira Boechat","year":"2023","unstructured":"de Oliveira Boechat T, de Holanda Farias JS, Ribeiro EFO, de Andrade MLL. Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program. Ann Hematol. 2023;102(6):1581\u20138.","journal-title":"Ann Hematol"},{"issue":"5","key":"854_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","volume":"10","author":"M R\u00e9ti","year":"2012","unstructured":"R\u00e9ti M, Farkas P, Csuka D, R\u00e1zs\u00f3 K, Schlammadinger \u00c1, Udvardy ML, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791\u20138.","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00854-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:51:19Z","timestamp":1781643079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00854-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00854-9","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the patient\u2019s personal identification was mentioned in the manuscript. Written consent for publishing anonymized case details was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors and patient families agree to publish this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}